دورية أكاديمية
Anti-SIRP α antibodies as a potential new tool for cancer immunotherapy.
| العنوان: | Anti-SIRP α antibodies as a potential new tool for cancer immunotherapy. |
|---|---|
| المؤلفون: | Yanagita T; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology.; Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan., Murata Y; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Tanaka D; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Motegi SI; Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan., Arai E; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.; Department of Pathology, Keio University School of Medicine, Tokyo, Japan., Daniwijaya EW; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Hazama D; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Washio K; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Saito Y; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Kotani T; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology., Ohnishi H; Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan., Oldenborg PA; Department of Integrative Medical Biology, Section for Histology and Cell Biology, Umeå University, Umeå, Sweden., Garcia NV; Laboratory of Immunodynamics, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Osaka, Japan., Miyasaka M; Laboratory of Immunodynamics, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.; MediCity Research Laboratory, University of Turku, Turku, Finland., Ishikawa O; Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan., Kanai Y; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.; Department of Pathology, Keio University School of Medicine, Tokyo, Japan., Komori T; Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan., Matozaki T; Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology. |
| المصدر: | JCI insight [JCI Insight] 2017 Jan 12; Vol. 2 (1), pp. e89140. Date of Electronic Publication: 2017 Jan 12. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Print ISSN: 2379-3708 (Print) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
| مواضيع طبية MeSH: | CD47 Antigen/*metabolism , CD8-Positive T-Lymphocytes/*metabolism , Immunotherapy/*methods , Neoplasms/*therapy , Receptors, Immunologic/*antagonists & inhibitors, Adult ; Aged ; Aged, 80 and over ; Animals ; Antigens, Differentiation/immunology ; Antigens, Differentiation/metabolism ; Antigens, Differentiation/therapeutic use ; CD47 Antigen/drug effects ; CD8-Positive T-Lymphocytes/drug effects ; Carcinoma, Renal Cell/metabolism ; Female ; Humans ; Macrophages/drug effects ; Macrophages/metabolism ; Male ; Melanoma/metabolism ; Mice ; Middle Aged ; Neoplasms/immunology ; Phagocytosis/drug effects ; Receptors, Immunologic/immunology ; Receptors, Immunologic/metabolism ; Receptors, Immunologic/therapeutic use ; Tumor Microenvironment/immunology |
| مستخلص: | Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRPα is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRPα Ab that blocks the interaction with CD47 markedly suppressed tumor formation by renal cell carcinoma or melanoma cells in immunocompetent syngeneic mice. This inhibitory effect of the Ab appeared to be mediated by dual mechanisms: direct induction of Ab-dependent cellular phagocytosis of tumor cells by macrophages and blockade of CD47-SIRPα signaling that negatively regulates such phagocytosis. The antitumor effect of the Ab was greatly attenuated by selective depletion not only of macrophages but also of NK cells or CD8 + T cells. In addition, the anti-SIRPα Ab also enhances the inhibitory effects of Abs against CD20 and programmed cell death 1 (PD-1) on tumor formation in mice injected with SIRPα-nonexpressing tumor cells. Anti-SIRPα Abs thus warrant further study as a potential new therapy for a broad range of cancers. Competing Interests: The authors have declared that no conflict of interest exists. |
| References: | Cancer Lett. 2015 Feb 28;357(2):454-67. (PMID: 25511743) EMBO J. 2003 Jun 2;22(11):2634-44. (PMID: 12773380) Cancer Res. 2016 Feb 1;76(3):513-6. (PMID: 26772756) Cancer Res. 2014 Dec 1;74(23):6771-83. (PMID: 25297630) Pathol Int. 2015 Apr;65(4):170-6. (PMID: 25707506) Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395) Nature. 1981 May 28;291(5813):334-5. (PMID: 7231554) Trends Cell Biol. 2009 Feb;19(2):72-80. (PMID: 19144521) ISRN Hematol. 2013;2013:614619. (PMID: 23401787) Curr Opin Immunol. 2016 Apr;39:1-6. (PMID: 26609943) J Biol Chem. 2004 Jul 9;279(28):29450-60. (PMID: 15123631) Curr Opin Immunol. 2012 Apr;24(2):225-32. (PMID: 22310103) Blood. 1994 Jan 15;83(2):435-45. (PMID: 7506951) J Immunol. 2005 Feb 15;174(4):2004-11. (PMID: 15699129) Dev Biol. 1990 Feb;137(2):219-32. (PMID: 2303162) Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. (PMID: 22451913) Mol Cell Proteomics. 2005 Dec;4(12):1920-32. (PMID: 16127175) Nat Immunol. 2007 Dec;8(12):1313-23. (PMID: 17982459) Neoplasia. 2004 Sep-Oct;6(5):558-68. (PMID: 15548365) Nat Med. 2015 Oct;21(10):1209-15. (PMID: 26322579) J Neurosci. 2005 Mar 9;25(10):2702-11. (PMID: 15758180) Immunity. 2011 Jan 28;34(1):85-95. (PMID: 21194983) BMC Med. 2012 Mar 02;10:23. (PMID: 22385436) Int J Cancer. 2015 Dec 1;137(11):2589-606. (PMID: 26061684) Blood. 2006 Jan 1;107(1):341-8. (PMID: 16141346) FEBS J. 2016 Jul;283(14):2731-48. (PMID: 26787424) Blood. 2012 May 3;119(18):4333-4; author reply 4334-5. (PMID: 22555661) Hepatology. 2013 Aug;58(2):680-91. (PMID: 23504854) Nat Commun. 2016 Jul 06;7:12150. (PMID: 27381735) Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54. (PMID: 27091975) Clin Cancer Res. 2009 Mar 1;15(5):1623-34. (PMID: 19208793) Cell. 2010 Sep 3;142(5):699-713. (PMID: 20813259) J Immunother Cancer. 2016 Mar 15;4:15. (PMID: 26981245) Crit Rev Oncol Hematol. 2016 Feb;98 :242-53. (PMID: 26616525) Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18342-7. (PMID: 22042861) Science. 2000 Jun 16;288(5473):2051-4. (PMID: 10856220) J Clin Oncol. 1999 Aug;17(8):2530-40. (PMID: 10561319) J Vis Exp. 2012 Aug 01;(66):4105. (PMID: 22871793) PLoS One. 2015 Sep 21;10(9):e0137345. (PMID: 26390038) Cancer Res. 2005 Apr 15;65(8):3437-46. (PMID: 15833879) J Neuroimmunol. 1988 Jan;17(2):147-57. (PMID: 2447125) J Immunol. 2007 May 15;178(10):6164-72. (PMID: 17475843) J Immunol. 2009 Apr 1;182(7):4415-22. (PMID: 19299742) Hum Vaccin Immunother. 2015;11(5):1201-8. (PMID: 25912622) J Cutan Pathol. 2008 May;35(5):433-44. (PMID: 18399807) Nature. 2002 Oct 17;419(6908):734-8. (PMID: 12384702) Nature. 2012 Mar 28;483(7391):603-7. (PMID: 22460905) Nat Immunol. 2013 Dec;14(12):1212-8. (PMID: 24240160) Annu Rev Immunol. 2014;32:25-50. (PMID: 24215318) Immunol Lett. 2008 Nov 16;121(1):52-60. (PMID: 18809435) Elife. 2014 Aug 22;3:e04177. (PMID: 25149452) J Immunol. 2015 Sep 15;195(6):2818-28. (PMID: 26276870) Blood. 2001 May 1;97(9):2741-9. (PMID: 11313266) Int Immunol. 2005 Feb;17(2):133-44. (PMID: 15611321) J Innate Immun. 2014;6(4):553-60. (PMID: 24516072) J Clin Oncol. 2009 Aug 1;27(22):3584-90. (PMID: 19487381) J Immunol. 2005 Dec 15;175(12):7781-7. (PMID: 16339510) J Immunol. 2011 Sep 1;187(5):2268-77. (PMID: 21775684) Cancer Cell. 2012 Mar 20;21(3):309-22. (PMID: 22439926) Blood. 2010 Nov 4;116(18):3517-25. (PMID: 20682853) |
| المشرفين على المادة: | 0 (Antigens, Differentiation) 0 (CD47 Antigen) 0 (CD47 protein, human) 0 (Receptors, Immunologic) 0 (SIRPA protein, human) |
| تواريخ الأحداث: | Date Created: 20170119 Date Completed: 20190613 Latest Revision: 20190613 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5214103 |
| DOI: | 10.1172/jci.insight.89140 |
| PMID: | 28097229 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!